MedTrace Logo

Umbilical Cord Blood Therapy for Children With Global Developmental Delay

NCT01601158 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-01-09

No results posted yet for this study

Summary

This open-label study aims to evaluate the safety and efficacy of umbilical cord blood therapy for children with global developmental delay.

Conditions

  • Global Developmental Delay

Interventions

BIOLOGICAL

Umbilical Cord Blood administration

The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.

OTHER

Active Rehabilitation

All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.

Sponsors & Collaborators

  • MinYoung Kim, M.D.

    lead OTHER

Principal Investigators

  • Minyoung Kim, M.D., Ph.D. · CHA University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01601158 on ClinicalTrials.gov